Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated an Outperform rating on Travere Therapeutics (NASDAQ:TVTX) and maintained a $12 price target.
September 29, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico has reiterated an Outperform rating on Travere Therapeutics and maintained a $12 price target.
The reiteration of an Outperform rating by a reputable analyst like Laura Chico from Wedbush is a positive signal for Travere Therapeutics. The maintained price target of $12 also indicates a positive outlook for the stock. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100